Are national cardiac guidelines being applied by vascular surgeons?

European Journal of Vascular and Endovascular Surgery

Volumn 26, Issue 6, 2003, Pages 623-628

  Cassar, K ^a   Belch, J J F ^b   Brittenden, J ^a,c  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

Antiplatelet therapy; Cholesterol; Exercise; Intermittent claudication; Risk factors; Smoking

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CHOLESTEROL; CLOPIDOGREL; DIPYRIDAMOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LANSOPRAZOLE;

ARTICLE; BLOOD PRESSURE MEASUREMENT; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CONSULTATION; CONTROLLED STUDY; DIABETES MELLITUS; DIET THERAPY; DOSE RESPONSE; EXERCISE; HUMAN; INTERMITTENT CLAUDICATION; ISCHEMIC HEART DISEASE; MEDICAL SOCIETY; NICOTINE REPLACEMENT THERAPY; OUTPATIENT CARE; PHYSICIAN ATTITUDE; POSTAL MAIL; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR; SMOKING; SMOKING CESSATION; SURGEON; THROMBOPHILIA; VASCULAR SURGERY;

EID: 0344465377     PISSN: 10785884     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejvs.2003.08.001     Document Type: Article

References (25)

1. Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation 1985; 71(3): 510-515.
2. Leng GC, Lee AJ, Fowkes FGR, Whiteman M, Dunbar J, Housley E, Vaughan Ruckley. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epid 1996; 25: 1172-1181.
3. Housley E. Treating claudication in 5 words. BMJ 1988; 1483-1484.
4. Wood D, Durrington P, Poulter N, McInnes G, Rees A, Wray R. Joint British Recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80(Suppl. 2): S1-S29.
5. Intercollegiate Guidelines Network (SIGN) Drug therapy for peripheral vascualr disease, publication number 27, July 1998.
6. Cassar K, Coull R, Bachoo F, Macaulay E, Brittenden J. Primary care risk factor management in claudicants. Eur J Vasc Endovasc Surg 2003; 26: 145-149.
7. Vray M, Chwalow J, Charansonney O et al. National study of obliterative disease of the lower limbs involving general practitionaires in France: Attemio study. J Cardiovasc Pharmacol 1995; 25(Suppl.): S51-S57.
8. Donnelly R, Yeung JMC. Management of intermittent claudication: the importance of secondary prevention. Eur J Vasc Endovasc Surg 2002; 23: 100-107.
9. Burns P, Lima E, Bradbury AW. What constitutes best medical therapy for peripheral arterial disease? Eur J Vasc Eadovasc Surg 2002; 24: 6-12.
10. Burns P, Lima E, Bradbury AW. Second best medical therapy. Eur J Vasc Endovasc Surg 2002; 24: 400-410.
11. Pedersen TF, Kjeksus J, Berg K, for the Scandinavian Simvastatin Survival Study Group et al. Baseline serum cholesterol and treatment effect in the Scandinavian simvastatin survival study. Lancet 1995; 345: 1274-1275.
12. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
13. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group, Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
14. Tang JL, Armitage JM, Lancaster T, Silagy CA, Fowler GH, Neil HAW. Systemic review of dietary intervention trials to lower blood total cholesterol in free-living subjects. BMJ 1998; 316: 1213-1219.
15. Heart Protection Study Collaborative Group, MRC/BHF Heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo controlled trial. Lancet 2002; 360: 7-22.
16. Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: The Framingham study. J Am Geriatr Soc 1985; 33: 13-18.
17. Belch JJF. Metabolic, endocrin and haemodynamic risk factors in the patient with peripheral arterial disease. Diabetes, Obesity & Metabolism 2002; 4(Suppl 2): S7-S13.
18. Rosenberg L, Palmer JR, Shapiro S. Decline in the risk of myocardial infarction among women who stop smoking. N Engl J Med 1990; 322: 214-217.
19. Silagy C, Mant D, Fowler G, Lodge M. Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet 1994; 343: 139-142.
20. Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication (Cochrane Review). The Cochrane Library. Oxford: Update Software, 2002. Issue 1.
21. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999; 354: 407-413.
22. Caldwell S, McCarthy M, Martin SC et al. Hyperhomocysteineamia, peripheral vascular disease and neo-intimal hyperplasia in elderly patients. Br J Surg 1998; 83: 709.
23. Foley PW, Irvine CD, Standen GR et al. Activated protein C rersistance, factor V Leiden and peripheral vascular disease. Cardiovasc Surg 1997; 5: 157-160.
24. Sampram ES, Lindblad B, Dahlback B. Activated protein C resistance in patients with peripheral vascular disease. J Vasc Surg 1998; 28: 64-67.
25. Burns PJ, Mosquera DA, Bradbury AW. Prevalence and significance of thrombophilia in peripheral arterial disease. Eur J Vasc Endovasc Surg 2002; 22: 22-98. see also 24-30.